iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
Why now
Thesis: Early-stage cell therapy advances toward trials
Catalyst to watch: Trial enrollment and early data
Main risk: Clinical failure risk remains high
Why it matters
Clinical trial clearance advances a pipeline but is early-stage with no near-term revenue.
Details
- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. CHENGDU, China, Sept. 29, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering...
Related assets & topics
ChinaHealthcareSources
- prnewswire · 2026-09-29 05:41 UTC